These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 31415033)

  • 1. mTOR Inhibitor Therapy Diminishes Circulating CD8+ CD28- Effector Memory T Cells and Improves Allograft Inflammation in Belatacept-refractory Renal Allograft Rejection.
    Castro-Rojas CM; Godarova A; Shi T; Hummel SA; Shields A; Tremblay S; Alloway RR; Jordan MB; Woodle ES; Hildeman DA
    Transplantation; 2020 May; 104(5):1058-1069. PubMed ID: 31415033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Belatacept-Resistant Rejection Is Associated With CD28
    Mathews DV; Wakwe WC; Kim SC; Lowe MC; Breeden C; Roberts ME; Farris AB; Strobert EA; Jenkins JB; Larsen CP; Ford ML; Townsend R; Adams AB
    Am J Transplant; 2017 Sep; 17(9):2285-2299. PubMed ID: 28502128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased Pretransplant Frequency of CD28
    Cortes-Cerisuelo M; Laurie SJ; Mathews DV; Winterberg PD; Larsen CP; Adams AB; Ford ML
    Am J Transplant; 2017 Sep; 17(9):2350-2362. PubMed ID: 28502091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Postdepletion Lymphocyte Reconstitution During Belatacept and Rapamycin Treatment in Kidney Transplant Recipients.
    Xu H; Samy KP; Guasch A; Mead SI; Ghali A; Mehta A; Stempora L; Kirk AD
    Am J Transplant; 2016 Feb; 16(2):550-64. PubMed ID: 26436448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Belatacept and sirolimus prolong nonhuman primate renal allograft survival without a requirement for memory T cell depletion.
    Lo DJ; Anderson DJ; Weaver TA; Leopardi F; Song M; Farris AB; Strobert EA; Jenkins J; Turgeon NA; Mehta AK; Larsen CP; Kirk AD
    Am J Transplant; 2013 Feb; 13(2):320-8. PubMed ID: 23311611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sirolimus vs mycophenolate moftile in Tacrolimus based therapy following induction with Antithymocyte globulin promotes regulatory T cell expansion and inhibits RORγt and T-bet expression in kidney transplantation.
    Jamali S; Sarafnejad A; Ahmadpoor P; Nafar M; Karimi M; Eteghadi A; Yekaninejad MS; Amirzargar AA
    Hum Immunol; 2019 Sep; 80(9):739-747. PubMed ID: 30597187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Belatacept for Simultaneous Calcineurin Inhibitor and Chronic Corticosteroid Immunosuppression Avoidance: Two-Year Results of a Prospective, Randomized Multicenter Trial.
    Kaufman DB; Woodle ES; Shields AR; Leone J; Matas A; Wiseman A; West-Thielke P; Sa T; King EC; Alloway RR;
    Clin J Am Soc Nephrol; 2021 Sep; 16(9):1387-1397. PubMed ID: 34233921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-CD28 Antibody and Belatacept Exert Differential Effects on Mechanisms of Renal Allograft Rejection.
    Ville S; Poirier N; Branchereau J; Charpy V; Pengam S; Nerriere-Daguin V; Le Bas-Bernardet S; Coulon F; Mary C; Chenouard A; Hervouet J; Minault D; Nedellec S; Renaudin K; Vanhove B; Blancho G
    J Am Soc Nephrol; 2016 Dec; 27(12):3577-3588. PubMed ID: 27160407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ASP2409, A Next-Generation CTLA4-Ig, Versus Belatacept in Renal Allograft Survival in Cynomolgus Monkeys.
    Song L; Ma A; Dun H; Hu Y; Fujii Y; Kinugasa F; Oshima S; Higashi Y; Daloze P; Chen H
    Am J Transplant; 2017 Mar; 17(3):635-645. PubMed ID: 27598231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: a viable option?
    Höcker B; Tönshoff B
    Paediatr Drugs; 2011 Feb; 13(1):49-69. PubMed ID: 21162600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective targeting of human alloresponsive CD8+ effector memory T cells based on CD2 expression.
    Lo DJ; Weaver TA; Stempora L; Mehta AK; Ford ML; Larsen CP; Kirk AD
    Am J Transplant; 2011 Jan; 11(1):22-33. PubMed ID: 21070604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conversion to Belatacept based regimen does not change T-cell phenotype and function in renal transplantation.
    Matz M; Fabritius K; Liu J; Lorkowski C; Brakemeier S; Unterwalder N; Dürr M; Mashreghi MF; Neumayer HH; Budde K
    Transpl Immunol; 2015 Nov; 33(3):176-84. PubMed ID: 26478531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Belatacept in kidney transplantation.
    Wojciechowski D; Vincenti F
    Curr Opin Organ Transplant; 2012 Dec; 17(6):640-7. PubMed ID: 23044530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Randomized Controlled Clinical Trial Comparing Belatacept With Tacrolimus After De Novo Kidney Transplantation.
    de Graav GN; Baan CC; Clahsen-van Groningen MC; Kraaijeveld R; Dieterich M; Verschoor W; von der Thusen JH; Roelen DL; Cadogan M; van de Wetering J; van Rosmalen J; Weimar W; Hesselink DA
    Transplantation; 2017 Oct; 101(10):2571-2581. PubMed ID: 28403127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Down-Regulation of Surface CD28 under Belatacept Treatment: An Escape Mechanism for Antigen-Reactive T-Cells.
    de Graav GN; Hesselink DA; Dieterich M; Kraaijeveld R; Weimar W; Baan CC
    PLoS One; 2016; 11(2):e0148604. PubMed ID: 26919152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Acute Cellular Rejection With Detrimental Outcome Occurring Under Belatacept-Based Immunosuppressive Therapy: An Immunological Analysis.
    de Graav GN; Hesselink DA; Dieterich M; Kraaijeveld R; Douben H; de Klein A; Roelen DL; Weimar W; Roodnat JI; Clahsen-van Groningen MC; Baan CC
    Transplantation; 2016 May; 100(5):1111-9. PubMed ID: 26599491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunosuppressive minimization with mTOR inhibitors and belatacept.
    Diekmann F
    Transpl Int; 2015 Aug; 28(8):921-7. PubMed ID: 25959589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Donor-Derived Regulatory Dendritic Cell Infusion Maintains Donor-Reactive CD4
    Ezzelarab MB; Lu L; Shufesky WF; Morelli AE; Thomson AW
    Front Immunol; 2018; 9():250. PubMed ID: 29520267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eomesodermin(lo) CTLA4(hi) Alloreactive CD8+ Memory T Cells Are Associated With Prolonged Renal Transplant Survival Induced by Regulatory Dendritic Cell Infusion in CTLA4 Immunoglobulin-Treated Nonhuman Primates.
    Ezzelarab MB; Lu L; Guo H; Zahorchak AF; Shufesky WF; Cooper DK; Morelli AE; Thomson AW
    Transplantation; 2016 Jan; 100(1):91-102. PubMed ID: 26680373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Homeostatic repopulation by CD28-CD8+ T cells in alemtuzumab-depleted kidney transplant recipients treated with reduced immunosuppression.
    Trzonkowski P; Zilvetti M; Chapman S; Wieckiewicz J; Sutherland A; Friend P; Wood KJ
    Am J Transplant; 2008 Feb; 8(2):338-47. PubMed ID: 18211507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.